Browsing by Subject "PHASE-2"

Sort by: Order: Results:

Now showing items 1-3 of 3
  • Eskelund, Christian W.; Kolstad, Arne; Jerkeman, Mats; Räty, Riikka; Laurell, Anna; Eloranta, Sandra; Smedby, Karin E.; Husby, Simon; Pedersen, Lone B.; Andersen, Niels S.; Eriksson, Mikael; Kimby, Eva; Bentzen, Hans; Kuittinen, Outi; Lauritzsen, Grete F.; Nilsson-Ehle, Herman; Ralfkiaer, Elisabeth; Ehinger, Mats; Sundstrom, Christer; Delabie, Jan; Karjalainen-Lindsberg, Marja-Liisa; Workman, Christopher T.; Garde, Christian; Elonen, Erkki; Brown, Peter; Gronbaek, Kirsten; Geisler, Christian H. (2016)
    In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 114years: For all patients on an intent-to-treat basis, the median overall and progression-free survival was 127 and 85years, respectively. The MCL International Prognostic Index (MIPI), biological MIPI, including Ki67 expression (MIPI-B) and the MIPI-B including mIR-18b expression (MIPI-B-miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12years, we still see an excess disease-related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.
  • Escudero, Javier; Heredia-Soto, Victoria; Wang, Yinyin; Ruiz, Patricia; Hu, Yingying; Gallego, Alejandro; Pozo-Kreilinger, Jose Juan; Martinez-Marin, Virginia; Berjon, Alberto; Ortiz-Cruz, Eduardo; Bernabeu, Daniel; Feliu, Jaime; Tang, Jing; Redondo, Andres; Mendiola, Marta (2021)
    Background Eribulin has shown antitumour activity in some soft tissue sarcomas (STSs), but it has only been approved for advanced liposarcoma (LPS). Methods In this study, we evaluated the effect of eribulin on proliferation, migration and invasion capabilities in LPS, leiomyosarcoma (LMS) and fibrosarcoma (FS) models, using both monolayer (2D) and three-dimensional (3D) spheroid cell cultures. Additionally, we explored combinations of eribulin with other drugs commonly used in the treatment of STS with the aim of increasing its antitumour activity. Results Eribulin showed activity inhibiting proliferation, 2D and 3D migration and invasion in most of the cell line models. Furthermore, we provide data that suggest, for the first time, a synergistic effect with ifosfamide in all models, and with pazopanib in LMS as well as in myxoid and pleomorphic LPS. Conclusions Our results support the effect of eribulin on LPS, LMS and FS cell line models. The combination of eribulin with ifosfamide or pazopanib has shown in vitro synergy, which warrants further clinical research.
  • Kolstad, Arne; Pedersen, Lone Bredo; Eskelund, Christian W.; Husby, Simon; Gronbaek, Kirsten; Jerkeman, Mats; Laurell, Anna; Räty, Riikka; Elonen, Erkki; Andersen, Niels Smedegaard; Brown, Peter deNully; Kimby, Eva; Bentzen, Hans; Sundstrom, Christer; Ehinger, Mats; Karjalainen-Lindsberg, Marja-Liisa; Delabie, Jan; Ralfkiaer, Elisabeth; Fagerli, Unn-Merete; Nilsson-Ehle, Herman; Lauritzsen, Grete Fossum; Kuittinen, Outi; Niemann, Carsten; Geisler, Christian Hartman; Nordic Lymphoma Grp (2017)
    The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rear-rangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P